Targeting the metabolically overactivated cells in the different pathogenic microenvironments and selectively reprogramming their cell metabolisms can be a very prominent therapeutic strategy to cure a multitude of diseases, such as autoinflammatory /autoimmune disorders (Inflammatory Bowel Disease, Rheumatoid Arthritis, Interstitial Lung Disease, Ankylosing Spondylitis), pro-fibrotic disorders (Idiopathic Pulmonary Fibrosis, Fibrostenosis, Progressive Fibrosing Interstitial Lung Disease), and neuroinflammatory /neurodegenerative diseases (Multiple Sclerosis, Amyotrophic Lateral Sclerosis, Charcot-Marie-Tooth Disease).
